Span Divergent Quarterly Results for Trading Insights
In Sept 2025, Span Divergent (SDL) reported revenue ₹8 Cr and net profit ₹0 Cr — revenue +166.7% YoY. Compare with SDL fair price to assess whether the stock is under or overvalued.
SDL Quarterly Results — Revenue, Profit & EPS Highlights
Span Divergent latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore SDL price movement history to track price trends across different timeframes.
- Revenue of ₹8 Cr in Sept 2025 (+700.0% vs Mar 2025, +166.7% vs Sept 2024)
- Operating Margin of -1.0% in Sept 2025 (+197.0pp vs Mar 2025)
- Earnings Per Share of ₹-0.34 in Sept 2025 (+81.8% vs Mar 2025)
Span Divergent Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SDL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8 | 1 | 2 | 3 | 4 | 700.0% | 166.7% |
| Net Profit (₹ Cr) | 0 | -1 | 0 | 0 | 1 | - | - |
| EBITDA (₹ Cr) | 0 | -1 | 0 | 0 | 1 | - | - |
| EPS (₹) | -0.34 | -1.87 | -0.31 | 0.09 | 1.62 | - | - |
| Operating Margin (%) | -1.0% | -198.0% | -81.0% | 5.0% | -2.0% | - | - |
SDL Share Price Trend — 1-Year Movement Across Quarterly Results
Span Divergent 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Span Divergent share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SDL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Span Divergent latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1880.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 144.6 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6893.0 | 2,860 | 689 | +7.1% | - | 24.1% | 265.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4429.2 | 3,219 | 591 | +11.3% | - | 18.4% | 252.5 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1399.5 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 203.7 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1321.9 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 498.8 |
All amounts in ₹ Crores